Clopidogrel + Ticagrelor
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Plaque, Atherosclerotic
Conditions
Plaque, Atherosclerotic
Trial Timeline
Sep 1, 2013 โ Aug 1, 2015
NCT ID
NCT01905566About Clopidogrel + Ticagrelor
Clopidogrel + Ticagrelor is a approved stage product being developed by AstraZeneca for Plaque, Atherosclerotic. The current trial status is completed. This product is registered under clinical trial identifier NCT01905566. Target conditions include Plaque, Atherosclerotic.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02211066 | Approved | Completed |
| NCT01905566 | Approved | Completed |
Competing Products
20 competing products in Plaque, Atherosclerotic